We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 01:00:00 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Amneal Pharmaceuticals Inc. (AMRX) Thursday said it received U.S. Food and Drug Administration approval for EluRyng, the first generic version of Merck & Co.'s (MRK) NuvaRing contraceptive.
The Bridgewater, N.J., pharmaceutical company said it has initiated commercialization activities for EluRyng, which it is manufacturing internally and launching Thursday.
NuvaRing had U.S. sales of about $976 million for the 12 months ended Oct. 31, Amneal said, citing healthcare data and analytics provider Iqvia.
Shares of Amneal, which closed Wednesday at $3.48, jumped nearly 17% in premarket trading Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 12, 2019 07:49 ET (12:49 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
